Based on the previous findings, the authors suggested that using SGLT-2 inhibitors for patients undergoing peritoneal dialysis might result in delayed peritoneal fibrosis, better ultrafiltration of water and toxins, and, eventually, a better survival rate [8]. Here, SLC5A2 is linked to Peritoneal Fibrosis.